LLY

770.92

+1.18%↑

JNJ

177.42

+0.4%↑

ABBV

221.42

+2.4%↑

UNH

340.3

-0.22%↓

AZN

77.91

+0.84%↑

LLY

770.92

+1.18%↑

JNJ

177.42

+0.4%↑

ABBV

221.42

+2.4%↑

UNH

340.3

-0.22%↓

AZN

77.91

+0.84%↑

LLY

770.92

+1.18%↑

JNJ

177.42

+0.4%↑

ABBV

221.42

+2.4%↑

UNH

340.3

-0.22%↓

AZN

77.91

+0.84%↑

LLY

770.92

+1.18%↑

JNJ

177.42

+0.4%↑

ABBV

221.42

+2.4%↑

UNH

340.3

-0.22%↓

AZN

77.91

+0.84%↑

LLY

770.92

+1.18%↑

JNJ

177.42

+0.4%↑

ABBV

221.42

+2.4%↑

UNH

340.3

-0.22%↓

AZN

77.91

+0.84%↑

Home・Aktien・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Open

BrancheGesundheitswesen

32.32 0.91

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

31.72

Max

32.73

Schlüsselkennzahlen
By Trading Economics
Einkommen	-5.8M 40M
Verkäufe	16M 200M
KGV Branchendurchschnitt	11.558 35.664
EPS	0.92
Gewinnspanne	19.839
Angestellte	268
EBITDA	3M 59M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+56.03% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	28. Okt. 2025

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	21M 2.1B
Vorheriger Eröffnungskurs	31.41
Vorheriger Schlusskurs	32.32

Nachrichtenstimmung

By Acuity

20%

80%

43 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

29.8 / N/A Unterstützung & Widerstand

Harmony Biosciences Holdings Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. Sept. 2025, 17:03 UTC

Wichtige Markttreiber

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16. Sept. 2025, 16:49 UTC

Wichtige Markttreiber

Akquisitionen, Fusionen, Übernahmen

GD Culture Shares Drop After Deal for Pallas Capital

16. Sept. 2025, 16:11 UTC

Wichtige Markttreiber

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16. Sept. 2025, 23:40 UTC

Market Talk

Nikkei May Decline as Yen Strengthens -- Market Talk

16. Sept. 2025, 23:34 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16. Sept. 2025, 23:20 UTC

Market Talk

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16. Sept. 2025, 21:10 UTC

Akquisitionen, Fusionen, Übernahmen

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16. Sept. 2025, 20:51 UTC

Market Talk

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16. Sept. 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

16. Sept. 2025, 20:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

16. Sept. 2025, 20:25 UTC

Ergebnisse

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16. Sept. 2025, 20:24 UTC

Ergebnisse

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16. Sept. 2025, 19:19 UTC

Market Talk

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16. Sept. 2025, 18:52 UTC

Market Talk

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16. Sept. 2025, 18:44 UTC

Market Talk

Global Equities Roundup: Market Talk

16. Sept. 2025, 18:44 UTC

Market Talk

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16. Sept. 2025, 18:40 UTC

Akquisitionen, Fusionen, Übernahmen

Details Emerge on U.S.-China TikTok Deal -- WSJ

16. Sept. 2025, 18:38 UTC

Market Talk

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16. Sept. 2025, 18:19 UTC

Market Talk

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16. Sept. 2025, 18:01 UTC

Market Talk

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16. Sept. 2025, 17:34 UTC

Market Talk

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16. Sept. 2025, 16:53 UTC

Ergebnisse

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16. Sept. 2025, 16:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

16. Sept. 2025, 16:15 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Global Commodities Roundup: Market Talk

16. Sept. 2025, 16:09 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Global Energy Roundup: Market Talk

16. Sept. 2025, 16:09 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16. Sept. 2025, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16. Sept. 2025, 15:35 UTC

Market Talk

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16. Sept. 2025, 15:22 UTC

Market Talk

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16. Sept. 2025, 15:21 UTC

Market Talk

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Peer-Vergleich

Kursveränderung

Harmony Biosciences Holdings Inc Prognose

Kursziel

By TipRanks

56.03% Vorteil

12-Monats-Prognose

Durchschnitt 50.71 USD 56.03%

Hoch 70 USD

Tief 33 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Harmony Biosciences Holdings Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

8 ratings

Buy

Halten

Sell

Basierend auf 8 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Harmony Biosciences Holdings Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

29.8 / N/AUnterstützung & Widerstand

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Stimmung

By Acuity

43 / 371 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.